SOLENO THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
SOLENO THERAPEUTICS INC. - More news...
SOLENO THERAPEUTICS INC. - More news...
- Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock
- Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
- Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Soleno Therapeutics to Present at Upcoming February Investor Conferences
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics Strengthens Leadership Team with Key Appointments
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
- Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
- Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
- Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
- Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
- Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
- Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
- Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
- Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
- Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
- Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome